The WACC of AC Immune SA (ACIU) is 6.6%.
Range | Selected | |
Cost of equity | 5.7% - 7.5% | 6.6% |
Tax rate | 26.2% - 27.0% | 26.6% |
Cost of debt | 7.0% - 12.0% | 9.5% |
WACC | 5.7% - 7.5% | 6.6% |
Category | Low | High |
Long-term bond rate | 3.9% | 4.4% |
Equity market risk premium | 4.6% | 5.6% |
Adjusted beta | 0.4 | 0.47 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 5.7% | 7.5% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 0.03 | 0.03 |
Cost of debt | 7.0% | 12.0% |
After-tax WACC | 5.7% | 7.5% |
Selected WACC | 6.6% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
ACIU | AC Immune SA | 0.03 | 1.29 | 1.26 |
CLVS | Clovis Oncology Inc | 52.27 | 0.32 | 0.01 |
CNTG | Centogene NV | 10.02 | 1.39 | 0.17 |
DTIL | Precision BioSciences Inc | 0.47 | 0.24 | 0.18 |
KPTI | Karyopharm Therapeutics Inc | 6.88 | 1.37 | 0.23 |
OBSV | Obseva SA | 3.13 | 0.43 | 0.13 |
RIGL | Rigel Pharmaceuticals Inc | 0.17 | 2.09 | 1.86 |
VECT | VectivBio Holding AG | 0.01 | 0.07 | 0.07 |
XBIT | XBiotech Inc | 0.12 | 1.1 | 1.01 |
RLF.SW | RELIEF THERAPEUTICS Holding SA | 0.07 | -1.14 | -1.09 |
Low | High | |
Unlevered beta | 0.15 | 0.2 |
Relevered beta | 0.1 | 0.21 |
Adjusted relevered beta | 0.4 | 0.47 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for ACIU:
cost_of_equity (6.60%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (0.4) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.